Fig. 3From: CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countriesUse of a GLAs, b GLAs with demonstrated CV benefit and c selected CV medications. Data are % and were not weighted. Data are presented for the CAPTURE study sample overall and stratified by CVD status. In b, GLAs with demonstrated CV benefit were defined per 2020 American Diabetes Association guidelines [19] as GLP-1 RAs: dulaglutide, liraglutide, and semaglutide; and SGLT2is: canagliflozin, dapagliflozin, and empagliflozin. ACE angiotensin-converting enzyme, AGI alpha glucosidase inhibitor, ARB angiotensin II receptor blocker, CV cardiovascular, CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLA blood glucose-lowering agent, GLP-1 RA glucagon-like peptide-1 receptor agonist, SGLT2i sodium-glucose co-transporter-2 inhibitor, SU sulfonylurea, TZD thiazolidinedioneBack to article page